Benefits to Stem Cell Transplant for Patients With Multiple Myeloma
Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses the rationale for selecting stem cell transplant as treatment over a chemotherapy regimen for patients with multiple myeloma.
Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses the rationale for selecting stem cell transplant as treatment over a chemotherapy regimen for patients with multiple myeloma.
The alternative to stem cell transplantation is chronic therapy. While the stem cell transplant can be toxic and tough on the patient, Biran argues that it is still a better option for a patient than choosing to remain on chemotherapy for the rest of their life. Long-term chemotherapy can lead to a continual decline in cognitive function, quality of life, and patient reported outcomes.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
